Τίτλος:
Advances in biological therapies for dyslipidemias and atherosclerosis
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Atherosclerosis is a multifactorial disease influenced by genetics, lifestyle and environmental factors. Despite therapeutic advances that reduce the risk of cardiovascular events, atherosclerosis-related diseases remain the leading cause of mortality worldwide. Precise targeting of genes involved in lipoprotein metabolism is an emerging approach for atherosclerosis prevention and treatment. This article focuses on the latest developments, clinical potential and current challenges of monoclonal antibodies, vaccines and genome/transcriptome modification strategies, including antisense oligonucleotides, genome/base editing and gene therapy. Multiple lipid lowering biological therapies have already been approved by the FDA with impressive results to date, while many more promising targets are being pursued in clinical trials or pre-clinical animal models. © 2020 Elsevier Inc.
Συγγραφείς:
Valanti, E.-K.
Dalakoura-Karagkouni, K.
Siasos, G.
Kardassis, D.
Eliopoulos, A.G.
Sanoudou, D.
Περιοδικό:
Metabolism: Clinical and Experimental
Λέξεις-κλειδιά:
angiopoietin; angiopoietin like 3; angiopoietin related protein 4; antisense oligonucleotide; apolipoprotein B; apolipoprotein B100; apolipoprotein C3; apolipoprotein mimetic peptide; biological product; cholesterol ester transfer protein; icosapentaenoic acid ethyl ester; influenza vaccine; lipoprotein A; low density lipoprotein receptor; monoclonal antibody; oxidized low density lipoprotein; Pneumococcus vaccine; proprotein convertase 9; unclassified drug; vaccine, atherosclerosis; biological therapy; dyslipidemia; gene editing; gene targeting; gene therapy; human; immune response; inflammation; influenza; influenza vaccination; nonhuman; pneumococcal infection; priority journal; Review; signal transduction; transcriptomics; viral gene therapy; animal; atherosclerosis; biological therapy; dyslipidemia; endocrinology; experimental therapy; procedures, Animals; Atherosclerosis; Biological Therapy; Dyslipidemias; Endocrinology; Humans; Therapies, Investigational
DOI:
10.1016/j.metabol.2020.154461
